Summary
BeiGene, Ltd. (ONC) reported a significant increase in total revenues for the first quarter of 2021, reaching $605.9 million compared to $52.1 million in the prior year period. This growth was primarily driven by a substantial $499.8 million in collaboration revenue, largely attributed to the upfront payment from the Novartis agreement for tislelizumab, and a notable increase in product revenue, which grew by 103.8% to $106.1 million. The company's product revenue growth was fueled by strong performance of its internally developed drugs, BRUKINSA® and tislelizumab, along with the inclusion of XGEVA® in sales distribution. Despite the revenue surge, operating expenses also increased, with R&D expenses up 5.4% to $320.7 million and SG&A expenses up 70.1% to $182.1 million, reflecting ongoing investment in growth. Financially, the company reported a net income of $66.5 million for the quarter, a significant turnaround from the net loss of $364.9 million in the same period last year. This positive net income was substantially bolstered by the collaboration revenue. The company's liquidity remains strong, with cash, cash equivalents, and short-term investments totaling approximately $4.8 billion as of March 31, 2021, providing ample runway for its operations. Investors should note the substantial increase in SG&A expenses, which will be crucial to monitor as the company continues its global commercialization efforts.
Financial Highlights
54 data points| Revenue | $605.87M |
| Cost of Revenue | $32.69M |
| Gross Profit | $573.19M |
| R&D Expenses | $320.73M |
| SG&A Expenses | $182.11M |
| Operating Expenses | $535.71M |
| Operating Income | $70.17M |
| Interest Expense | $6.95M |
| Net Income | $55.58M |
| EPS (Basic) | $0.06 |
| EPS (Diluted) | $0.05 |
| Shares Outstanding (Basic) | 1.19B |
| Shares Outstanding (Diluted) | 1.26B |
Key Highlights
- 1Total revenues surged by 1,063.8% to $605.9 million in Q1 2021 from $52.1 million in Q1 2020.
- 2Collaboration revenue, primarily from the Novartis deal, amounted to $499.8 million, a significant contributor to the revenue growth.
- 3Product revenue increased by 103.8% to $106.1 million, driven by strong sales of BRUKINSA® and tislelizumab, and the addition of XGEVA®.
- 4The company reported a net income of $66.5 million for Q1 2021, a dramatic improvement from a net loss of $364.9 million in Q1 2020.
- 5Research and Development (R&D) expenses increased by 5.4% to $320.7 million, reflecting continued investment in the pipeline.
- 6Selling, General, and Administrative (SG&A) expenses increased by 70.1% to $182.1 million, supporting commercial expansion.
- 7Cash, cash equivalents, and short-term investments totaled $4.8 billion as of March 31, 2021, indicating a strong liquidity position.